← Back
$KROS All transactions

Keros Therapeutics, Inc.

▲ BUY 10b5-1 Plan
4 / 10

Conviction

$ Value

$12K

Shares

1,000

Price

$12

Filed

Apr 17

Why this score? (4/10)
  • Open market buy (+3)
  • Director (+1)

Insider

Name

BIENAIME JEAN JACQUES

Title

CIK

0001221590

Roles

Director

Transaction Details

Transaction Date

2026-04-15

Code

P

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

8,450

Footnotes

Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.56 to $11.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing Info

Accession No.

0001221590-26-000005

Form Type

4

Issuer CIK

0001664710

BIENAIME JEAN JACQUES's History

Date Ticker Type Value
2026-04-15 KROS $12K
2025-06-10 IMNM A $0
2025-06-10 INCY A $0
2025-06-10 INCY A $0
2025-06-04 KROS A $0
2025-06-04 KROS A $0
2025-06-03 IMNM $47K

Other Insiders at KROS (90d)

Insider Bought Sold Last
Seehra Jasbir
CHIEF EXECUTIVE OFFICER
2026-04-02
Cho Esther
Chief Legal Officer
2026-02-24